Search research articles
Contact Us
Filters
Showing results (281-290 of 305) with videos related to
Page
of 31
Sort By:
JTO Clinical and Research Reports
|
April 27, 2026
Durvalumab Plus Chemotherapy in Patients With <i>EGFR</i>-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD
Byoung Chul Cho, Makoto Nishio, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD
Sarah B Goldberg, Myung-Ju Ahn, Christina Baik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2017
Phase I Trial of Intratumoral Injection of <i>CCL21</i> Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8<sup>+</sup> T-cell Infiltration
Jay M Lee, Mi-Heon Lee, Edward Garon, et al.
The New England Journal of Medicine
|
April 21, 2015
Pembrolizumab for the treatment of non-small-cell lung cancer
Edward B Garon, Naiyer A Rizvi, Rina Hui, et al.
Cancer Discovery
|
May 25, 2016
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik, Lee S Rosen, Sara M Tolaney, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 6, 2025
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report
Gregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, et al.
Blood
|
March 18, 2026
Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models
Hongzhi Miao, Tao Wu, Trupta Purohit, et al.
The New England Journal of Medicine
|
October 23, 2023
Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions
Caicun Zhou, Ke-Jing Tang, Byoung Chul Cho, et al.
Journal for Immunotherapy of Cancer
|
February 1, 2023
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Neal E Ready, Clarisse Audigier-Valette, Jonathan W Goldman, et al.
JCO Precision Oncology
|
February 9, 2022
<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase Inhibitor
Jonathan W Goldman, Chris Karlovich, Lecia V Sequist, et al.
Page
of 31
Search research articles
Search
Showing results (281-290 of 305) with videos related to
Sort By:
Page
of 31
JTO Clinical and Research Reports
|
April 27, 2026
Durvalumab Plus Chemotherapy in Patients With <i>EGFR</i>-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD
Byoung Chul Cho, Makoto Nishio, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD
Sarah B Goldberg, Myung-Ju Ahn, Christina Baik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2017
Phase I Trial of Intratumoral Injection of <i>CCL21</i> Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8<sup>+</sup> T-cell Infiltration
Jay M Lee, Mi-Heon Lee, Edward Garon, et al.
The New England Journal of Medicine
|
April 21, 2015
Pembrolizumab for the treatment of non-small-cell lung cancer
Edward B Garon, Naiyer A Rizvi, Rina Hui, et al.
Cancer Discovery
|
May 25, 2016
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik, Lee S Rosen, Sara M Tolaney, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 6, 2025
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report
Gregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, et al.
Blood
|
March 18, 2026
Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models
Hongzhi Miao, Tao Wu, Trupta Purohit, et al.
The New England Journal of Medicine
|
October 23, 2023
Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions
Caicun Zhou, Ke-Jing Tang, Byoung Chul Cho, et al.
Journal for Immunotherapy of Cancer
|
February 1, 2023
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Neal E Ready, Clarisse Audigier-Valette, Jonathan W Goldman, et al.
JCO Precision Oncology
|
February 9, 2022
<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase Inhibitor
Jonathan W Goldman, Chris Karlovich, Lecia V Sequist, et al.
Page
of 31